GAP43 and neoplasm: Comparing tumours from the control group, the minimal residual disease stage and regrown tumours identified GAP43 as strongly differentially expressed, with a low expression at the minimal residual disease stage, but increasing in the regrown tumours (Fig. 7A–B).